Based on these observations, we hypothesized that the eradication of the TGFβ-LRRC15 signature in tumor cells would be synergistic with existing immunotherapies and allow for immune cell infiltration, similar to observations by Krishnamurty et al.8 The functional effects of the loss of this transcriptomic signature were investigated by our combination study of [177Lu]Lu-DUNP19 and immune checkpoint blockade. The gene discussed is TGFB1; the disease is neoplasm.